Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Evans

Plastic Surgery Orange, CA Medical Doctor

NPI 1962582007 CMS profile 44158

Uci Medical Center, 101 The City Drive South, Orange, CA 92868

Open in the dashboard

General payments

$6,662

62 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$36,249 paid to institutions, not to them · program year 2025

Through program year 2025, Gregory Evans of Orange, CA is reported in the CMS Open Payments database as having received $6,662 across 62 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $36,249 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 77th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $886 10
2024 General $1,461 15
2023 General $634 5
2022 General $2,481 17
2021 General $556 7
2020 General $131 2
2019 General $513 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Evans
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Gregory Evans were reported at $886. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Gregory Evans Plastic Surgery median Middle half National median
2019 $513 $371 $122–$1,483 $163
2020 $131 $158 $52–$438 $114
2021 $556 $249 $87–$752 $132
2022 $2,481 $274 $102–$793 $149
2023 $634 $299 $113–$891 $160
2024 $1,461 $361 $124–$1,062 $164
2025 $886 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mentor Worldwide LLC $1,471 16 payments
  2. Musculoskeletal Transplant Foundation Inc. $1,390 6 payments
  3. TELA Bio, Inc. $1,229 11 payments
  4. Sientra, Inc. $821 8 payments
  5. Motiva USA, LLC $398 4 payments
  6. Davol Inc. $155 2 payments
  7. Acera Surgical, Inc. $148 1 payment
  8. Kerecis Limited $145 1 payment
  9. AbbVie, Inc. $142 2 payments
  10. DePuy Synthes Sales Inc. $134 1 payment
  11. Other $629 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,509 59 payments
  2. Travel and Lodging $1,153 3 payments
Products named General payments · program years 2019–2025
  1. MENTOR MemoryGel Resterilizable Gel Sizer $1,241 14 payments
  2. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $821 8 payments
  3. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $618 6 payments
  4. OviTex 2S $611 5 payments
  5. Motiva Implant Matrix $398 4 payments
  6. MemoryGel Breast Implants $230 2 payments
  7. Phasix Mesh $155 2 payments
  8. Restrata Wound Matrix $148 1 payment
  9. Kerecis Omega3 SurgiClose $145 1 payment
  10. Kerecis Omega3 Marigen $145 1 payment
  11. Other $1,511 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

22

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$70

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

0%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 22 $70

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$33,347

Medicare's payments for the services billed

Medicare patients

44

Average age 75

Services billed

104

23 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Cancer 39%
Diabetes 34%
Ischemic heart disease 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

62 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record